₹1700
based on 4 analysts
75.00%
Buy
25.00%
Hold
0.00%
Sell
Based on 4 analysts offering long term price targets for Concord Biotech Ltd. An average target of ₹1621.5
Source: S&P Global Market Intelligence
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 11.66 % |
3 Month Return | + 5.17 % |
1 Year Return | + 82.54 % |
Market Stats | |
Previous Close | ₹1,720.95 |
Open | ₹1,700.00 |
Volume | 50.47K |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹18,003.93Cr |
P/E Ratio | 58.46 |
PEG Ratio | 9.02 |
Market Cap | ₹18,003.93 Cr |
P/B Ratio | 10.44 |
EPS | 29.45 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
![]() | BUY | ₹18,003.93 Cr | 16.51% | 0.50 | ₹308 Cr | ₹1,016 Cr |
![]() | BUY | ₹24,251.56 Cr | 13.4% | 0.53 | NA | NA |
![]() | NA | ₹531.11 Cr | 229.99% | 0.66 | ₹19 Cr | ₹251 Cr |
![]() | BUY | ₹10,461.37 Cr | 2.81% | 0.50 | NA | NA |
![]() | NA | ₹1,037.27 Cr | 301.68% | 0.64 | ₹10 Cr | ₹64 Cr |
Organisation | Concord Biotech Ltd |
Headquarters | Ahmedabad |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Concord Biotech Ltd
Over the past year, many insiders at Concord Biotech Limited have sold shares worth ₹159m. In the last three months, insider Kanishka Kapoor sold ₹144m worth of shares, indicating that some insiders may not consider the shares to be cheap. However, insiders own 50% of the company's shares, which could suggest that it is run in the interest of all shareholders.
Concord Biotech Receives GMP Certificate for Gujarat Facility - 06 Jun, 2024
Ireland's health products regulatory authority has issued an EU GMP certificate to Concord Biotech for Unit II of its Valthera facility in Gujarat, India.
Concord Biotech Shares Surge After Stake Sale And Upgrades - 29 May, 2024
Pharmaceutical company Concord Biotech's shares surged after Ontario Inc offloaded a stake worth Rs 519 crore and Kotak Institutional Equities upgraded the stock to add. Jefferies has a hold call on the stock with a target of Rs 1,410 per share.
Block Deal Sends Concord Biotech Shares Lower - 28 May, 2024
Ontario Inc planned to sell 3.4% stake in Concord Biotech via a block deal valued at Rs 468.4 crore. The transaction was completed with Citigroup as the sole book runner for the sale. Following the trade, the stock fell 2.4%. However, trading volumes surged over 66 times the two-week average daily volume.
Ontario Inc. Plans to Sell Stake in Concord Biotech - 27 May, 2024
Concord Biotech is set to see a block trade of 3.4% equity as shareholder Ontario Inc. plans to sell shares worth Rs 468.40 crore at a floor price of Rs 1,320 per share.
Concord Biotech Q4FY24 Profit Increases by 3.9% - 24 May, 2024
Concord Biotech Ltd reported a 3.9% increase in profit to Rs 95 crore and a 17% surge in revenue to Rs 319 crore for Q4FY24 compared to the same period last year.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
MF Holding Up
Mutual Funds have increased holdings from 5.58% to 5.65% in Dec 2023 quarter
Price Rise
In the last 7 days, CONCORDBIO stock has moved up by 2.5%
Retail Holding Up
Retail Investor have increased holdings from 40.44% to 40.46% in Dec 2023 quarter
Promoter Holding Unchanged
Promoters holdings remained unchanged at 44.08% of holdings in Dec 2023 quarter
Profit Down
Netprofit is down for the last 2 quarters, 81.02 Cr → 77.57 Cr (in ₹), with an average decrease of 4.3% per quarter
Revenue Fall
Revenue is down for the last 2 quarters, 270.47 Cr → 252.0 Cr (in ₹), with an average decrease of 6.8% per quarter
FII Holding Down
Foreign Institutions have decreased holdings from 7.30% to 7.00% in Dec 2023 quarter
Q'1 24 | Q/Q Change | |
---|---|---|
Revenue | ₹318.97Cr | ↑32.46% |
Net Income | ₹95.02Cr | ↑22.50% |
Net Profit Margin | 29.79% | ↓7.51% |
2024 | Y/Y Change | |
---|---|---|
Revenue | ₹1,016.94Cr | ↑19.20% |
Net Income | ₹308.10Cr | ↑28.33% |
Net Profit Margin | 30.30% | ↑7.68% |
2024 | Y/Y Change | |
---|---|---|
Total Assets | ₹1,701.77Cr | ↑12.19% |
Total Liabilities | ₹176.52Cr | ↓21.50% |
2024 | Y/Y Change | |
---|---|---|
Operating Cash Flow | ₹265.47Cr | ↑7.91% |
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 44.08% | 0.00 | |
Foreign Institutions | 7.11% | 9.63 | |
Mutual Funds | 5.26% | 2.23 | |
Retail Investors | 38.41% | ||
Others | 5.14% | 55.09 |
Concord Biotech Ltd in the last 5 years
Lowest (36.27x)
October 4, 2023
Industry (56.38x)
July 24, 2024
Today (58.46x)
July 24, 2024
Highest (58.46x)
July 24, 2024
Concord Biotech Ltd’s net profit jumped 3.86% since last year same period to ₹95.02Cr in the Q4 2023-2024. On a quarterly growth basis, Concord Biotech Ltd has generated 22.5% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2024, Concord Biotech Ltd has declared dividend of ₹8.75 - translating a dividend yield of 0.51%.
Read More about DividendsBearish
Neutral
Bullish
Concord Biotech Ltd is currently in a Bullish trading position according to technical analysis indicators.
Concord Biotech Ltd (CONCORDBIO) share price today is ₹1700
Concord Biotech Ltd is listed on NSE
Concord Biotech Ltd is listed on BSE
PE Ratio of Concord Biotech Ltd is 58.46
PE ratio = Concord Biotech Ltd Market price per share / Concord Biotech Ltd Earnings per share
Today’s traded volume of Concord Biotech Ltd(CONCORDBIO) is 50.47K.
Today’s market capitalisation of Concord Biotech Ltd(CONCORDBIO) is ₹18003.93Cr.
Concord Biotech Ltd(CONCORDBIO | Price |
---|---|
52 Week High | ₹1799 |
52 Week Low | ₹900.05 |
Concord Biotech Ltd(CONCORDBIO) share price is ₹1700. It is down -5.50% from its 52 Week High price of ₹1799
Concord Biotech Ltd(CONCORDBIO) share price is ₹1700. It is up 88.88% from its 52 Week Low price of ₹900.05
Concord Biotech Ltd(CONCORDBIO | Returns |
---|---|
1 Day Returns | -20.95% |
1 Month Returns | 11.66% |
3 Month Returns | 5.17% |
1 Year Returns | 82.54% |